AUSCANN GROUP HOLDINGS LTD |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.04 AUD | -4.76% |
|
-.--% | -.--% |
| Apr. 03 | AusCann Group Holdings Ltd Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
| Jan. 25 | AusCann Group Seeks to Raise Up to AU$1 Million Via Share Purchase Plan | MT |
Presenter SpeechElodie Castagna;FTI Consulting Strategic Communications;Director (Attendees)Go...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
AusCann Group Holdings Limited is an Australia-based company focused on the development and commercialization of cannabinoid-derived therapeutic products to address unmet needs for humans and animals within Australia and internationally. It has launched tetrahydrocannabinol and cannabidiol (THC/CBD) powder-based hard-shell capsules, based on the Companyâs Neuvis platform, for the treatment of pain and related indications. Its products include CPAT-01, DermaCann and MicroMax. CPAT-01 is a liquid, oral veterinary medicine containing standardized tetrahydrocannabinol (THC) and cannabinoids (CBD) whole plant extracts in a proprietary ratio to target pain and inflammation in dogs. DermaCann is a CBD-derived nutraceutical in development for healthy skin and immune function in dogs with dermatological conditions. The product is a liquid oral oil formulation containing CBD in a patented combination with other bioactive lipids designed to target inflammation and immune modulation pathways.
Sector
Pharmaceuticals
Calendar
2024-08-27
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 11.77M | |
| +37.78% | 705B | |
| +32.82% | 583B | |
| -3.51% | 364B | |
| +19.94% | 332B | |
| +5.14% | 291B | |
| +16.64% | 238B | |
| -4.13% | 210B | |
| +10.63% | 209B | |
| +9.32% | 169B |
- Stock Market
- Equities
- AC8 Stock
- News AusCann Group Holdings Ltd
- Transcript : AusCann Group Holdings Ltd - Special Call
